Shares of Bristol-Myers Squibb (NYSE:BMY), one of the largest pharmaceutical companies in the world, have been on a steady climb since the start of 2013. While Bristol is still facing headwinds from the patent expiration of its blockbuster drug, Plavix, recent clinical trial data have reignited investor enthusiasm for Bristol's long-term prospects. In the following segment from The Motley Fool's health care show, analysts David Williamson and Max Macaluso discuss three reasons investors might consider buying this pharma stock.

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.